Association between isotretinoin use and central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: a case report by Labiris, Georgios et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Medical Case Reports
Open Access Case report
Association between isotretinoin use and central retinal vein 
occlusion in an adolescent with minor predisposition for thrombotic 
incidents: a case report
Georgios Labiris*1, Andreas Katsanos1, Maria Karapetsa2, Ioanna Mpanaka2 
and Dimitrios Chatzoulis1
Address: 1Ophthalmology Department, University Hospital of Larissa, 41110 Larissa, Greece and 2Internal Medicine Department, University 
Hospital of Larissa, 41110 Larissa, Greece
Email: Georgios Labiris* - labiris@usa.net; Andreas Katsanos - andreakatbp@hotmail.com; Maria Karapetsa - mkarapetsa@gmail.gr; 
Ioanna Mpanaka - impanaka@yahoo.gr; Dimitrios Chatzoulis - d.chatzoulis@med.uth.gr
* Corresponding author    
Abstract
Introduction: We report an adolescent boy with minimal pre-existing risk for thromboses who
suffered central retinal vein occlusion associated with isotretinoin use for acne. To the best of our
knowledge, this is the first well documented case of this association.
Case presentation: An otherwise healthy 17-year-old white man who was treated with systemic
isotretinoin for recalcitrant acne was referred with central retinal vein occlusion in one eye.
Although a detailed investigation was negative, DNA testing revealed that the patient was a
heterozygous carrier of the G20210A mutation of the prothrombin gene. Despite the fact that this
particular mutation is thought to represent only a minor risk factor for thromboses, it is probable
that isotretinoin treatment greatly increased the risk of a vaso-occlusive incident in this patient.
Conclusion:  Isotretinoin use may be associated with sight- and life-threatening thrombotic
adverse effects even in young patients with otherwise minimal thrombophilic risk. Physicians should
be aware of such potential dangers.
Introduction
Isotretinoin, a vitamin A derivative, is a synthetic retinoid
used for the treatment of severe cystic acne that does not
respond to other therapies. The drug appears to act by
inhibiting sebaceous gland size and function. Besides
being teratogenic, a number of adverse effects have been
described for isotretinoin [1-3]. The most common ones
include dryness and itching of the skin and mucous mem-
branes. Less commonly reported adverse effects are head-
ache, inflammatory bowel disease, anorexia, alopecia,
pseudotumour cerebri, muscle and joint pains, as well as
premature closure of epiphyseal growth plates in chil-
dren's joints. An increase in serum lipid levels is also fre-
quently seen [4]. Previous reports have indicated an
association between isotretinoin use and thrombotic,
thromboembolic or haemorrhagic events whereas the
Canadian Adverse Reaction Newsletter described 11 such
cases of thromboembolic incidents, strokes and myocar-
dial infarctions for the period 1983–2005 [1-3].
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Case presentation
A 17-year-old white man was referred by his ophthalmol-
ogist to the University Department of Ophthalmology in
Larissa, Greece, with the diagnosis of central retinal vein
occlusion (CRVO) in his left eye. The patient's ophthalmic
history was negative, whereas his general medical history
was only significant for acne, for which he had been
treated with oral isotretinoin 20 mg three times daily (13-
cis-retinoic acid, Accutane®) for the previous 6 weeks. He
denied smoking, alcohol consumption and illicit sub-
stance use. The patient successfully participated in all reg-
ular sports activities at school, and presented a normal
body mass index of 23.77. Besides cheilitis with dry,
cracked and crusted lips, his initial physical examination
was negative.
His uncorrected visual acuity was 12/10 in each eye and
the intraocular pressure in his right and left eye was 14
and 17 mmHg, respectively. Funduscopy revealed optic
disc oedema with retinal haemorrhages and engorged,
tortuous veins in the left eye (Figure 1). His right eye had
a normal fundus with an optic nerve head having a cup-
to-disc ratio of 0.4. Visual fields examination revealed a
superior arcuate scotoma in his left eye (Figure 2).
A detailed clinical investigation of all systems, including
cardiovascular and neurological assessment was unre-
markable. Total blood count with differential, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and
routine laboratory testing were within normal ranges,
except for a mild increase in low-density lipoprotein
(LDL) cholesterol that was attributed to isotretinoin use.
Urine analysis and 24-hour urine selection specimens
were within normal ranges. Moreover, no viral or other
systemic or localised infection was detected. Further inves-
tigation with plasma protein electrophoresis, autoim-
mune and tumour markers, screening for
antiphospholipid syndrome, and cryoglobulinaemia was
also negative. Finally, the patient presented normal values
of protein C, protein S, antithrombin, and homocysteine.
DNA testing for potential genetic thrombophilic predis-
position revealed that the patient was a heterozygous car-
rier of the G20210A mutation of the prothrombin gene
(Table 1). However, his family history was negative for
thrombotic incidents even for senior relatives (grandpar-
ents). On the other hand, chest computed tomography
(CT), abdominal ultrasound, brain and orbit magnetic
resonance imaging (MRI) scans, as well as brain and orbit
magnetic resonance angiography (MRA), were all nega-
tive.
Isotretinoin treatment was discontinued and the patient
was initially given low molecular weight heparin, fol-
lowed by oral anticoagulants (acenocoumarol, Sintrom®).
Based on the notion that elevated intraocular pressure
may be a risk factor for CRVO, intraocular pressure lower-
ing medication was administered (brimonidine BID,
Alphagan®). Due to the patient's slow response to the treat-
ment, systemic steroids were added to the therapeutic
scheme (methylprednisolone sodium acetate 500 mg
intravenously for 3 days, then oral methylprednisolone
24 mg once daily for 1 month with gradual dosage
decrease). Six months after the CRVO, the optic disc
oedema had regressed and the haemorrhages had been
absorbed. The patient's visual acuity remains 12/10 with-
out signs of posterior- or anterior segment neovascularisa-
tion, whereas the visual field defect has slightly decreased
in depth. Cheilitis was attributed to isotretinoin and
resolved gradually after its discontinuation.
Discussion
Regarding the ocular adverse effects related to isotretinoin
[5,6], they can be categorised into the following classes
according to the World Health Organization classification
for causality of suspected drug-related events: "certain",
"probable/likely", "possible", "unlikely", "conditional/
unclassified" and "inaccessible/unclassifiable". Thus, the
"certain" category includes abnormal meibomian gland
secretion and atrophy, intracranial hypertension with
optic disc oedema, ocular sicca, corneal opacities, kerati-
tis, myopia and decreased dark adaptation. The "proba-
ble/likely" category includes reversible decreased colour
vision and permanent loss of dark adaptation. Adverse
events that have a "possible" association with isotretinoin
are permanent sicca, corneal ulcers, diplopia and eyelid
oedema. The "unlikely" category is comprised of entities
such as exophthalmos, keratoconus, glaucoma, activation
of herpes simplex and pupil abnormalities. The "condi-
tional/unclassified" and "inaccessible/unclassifiable" cat-
Funduscopic image of the left eye Figure 1
Funduscopic image of the left eye. Fundus photograph 
of the patient's left eye with optic disc oedema, retinal haem-
orrhages and engorged, tortuous veins. Photograph taken on 
the day of presentation.Journal of Medical Case Reports 2009, 3:58 http://www.jmedicalcasereports.com/content/3/1/58
Page 3 of 5
(page number not for citation purposes)
Visual field of the left eye Figure 2
Visual field of the left eye. Printout of the visual field test of the patient's left eye exhibiting a superior arcuate scotoma. 
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egories include a variety of events for which data are
insufficient or contradictory. It is noteworthy that
isotretinoin can have a significant effect on the cornea and
the ocular tear film [7,8]; this is of particular clinical rele-
vance because the age distribution of patients treated with
isotretinoin overlaps to a large extent with the age distri-
bution of patients undergoing very popular corneal refrac-
tive operations.
Regarding the patient presented in this report, although
the MTHFR C677T mutation is not associated with a
thrombotic diathesis, heterozygosity in the G20210A
mutation is considered to be a minor predisposing factor
for thrombotic incidents in otherwise healthy young
adults. However, the introduction of isotretinoin treat-
ment possibly initiated or facilitated the thrombotic proc-
ess. Besides previous reports that indicated an association
between isotretinoin use and thrombotic, thromboem-
bolic or haemorrhagic events [1,2], the Canadian Adverse
Reaction Newsletter described 11 such cases of throm-
boembolic incidents, strokes and myocardial infarctions
for the period 1983–2005 [3]. Nine of the patients were
aged 29 or younger, whereas four of the 11 patients had
no other risk factor. Paradoxically, some reports indicate a
possible protective effect of isotretinoin in thromboem-
bolic disorders. Some of the underlying mechanisms may
be the decrease in lipoprotein (a) which has been impli-
cated in coronary heart disease and stroke and the inhibi-
tion of vascular smooth muscle proliferation and vessel
remodelling [9,10]. Thus, the drug appears to act on the
coagulation process by a still unexplained mechanism.
Considering our patient, the relationship between
isotretinoin intake and CRVO is "probable" both accord-
ing to the Naranjo probability scale [11] and the World
Health Organization classification for causality of drug-
related reactions.
Conclusion
Oral isotretinoin treatment was associated with central
retinal vein occlusion in our adolescent male patient who
only had a minor genetic predisposition for thrombosis.
Although the occurrence of this sight-threatening adverse
event is rare, there is a probable relationship between
isotretinoin intake and CRVO. The risk of thrombotic
incidents even in young patients should be kept in mind
by prescribing physicians.
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